Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR) for Patients with Lung Tumors and Severe Pulmonary Disease

Journal of Clinical Medicine 2026 Open access

Read full text
Authors: Kenneth D. Westover, Ruiqi Li, Stetler Tanner, Maureen Aliru, Mu-Han Lin, Bin Cai, David Parsons, Justin Visak, Yesenia Gonzalez, Avnish Gill, Yuanyuan Zhang, Shahed N. Badiyan
+2 more Puneeth Iyengar, Robert Timmerman
DOI: 10.3390/jcm15031261
Cited by: 3
References: 26

Abstract

Background/Objectives: Patients with early-stage non-small cell lung cancer (NSCLC) or limited lung metastases and compromised lung function, such as those with interstitial lung disease (ILD) or chronic obstructive pulmonary disease (COPD), or other factors rendering them high-risk for surgery or medically inoperable, face increased risks of treatment-related toxicity from stereotactic ablative radiation therapy (SABR). This study evaluated a novel treatment approach to mitigate these risks. Methods: We investigated Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy (PULSAR), delivered as pulsed radiation every three weeks, in patients with

Fields of Study & Subjects

Radiomics and Machine Learning in Medical Imaging Lung Cancer Diagnosis and Treatment Advanced Radiotherapy Techniques

Publication details

Journal / source
Journal of Clinical Medicine
Publisher
MDPI AG
Volume
15
Issue
3
Pages
1261–1261
Publication date
5 February 2026
Language
EN